FindMyKOL
Clinical trialNCT01374191WithdrawnPhase 2Interventional

Botulinum Toxin Type A for Neuroma Pain

NCT01374191 is a phase 2 interventional trial sponsored by Southern Illinois University. As of 21 Nov 2026, it was withdrawn. It studies 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A in Neuroma. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2015 and a primary completion date of 31 May 2017.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01374191
FieldValue
Registry IDNCT01374191
StatusWithdrawn
PhasePhase 2
Study typeInterventional trial
Lead sponsorSouthern Illinois University
Enrollment0
Registered sites1
Countries1
ConditionsNeuroma
Drugs2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A
Start31 Jan 2015
Primary completion31 May 2017
Study completion30 Sept 2017
Last update posted26 Aug 2015

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if botulinum toxin type A (Btx-A) is an effective treatment for painful neuromas. The ideal therapy for painful neuromas would be effective, non-addictive, safe, localized, and cost-effective treatment. At the same time, the therapy would also address the complex peripheral and central mechanisms. Btx-A is a potential treatment that addresses each of these requirements while preserving the existing sensation and function. Study Hypothesis: Btx-A injection relieves neuroma pain better than a placebo

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Michael A. Neumeister, MD

    Southern Illinois University School of Medicine

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Illinois, United States1 site
  • Southern Illinois University School of Medicine

    Springfield

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1IndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

2nd phase - onabotulinum toxin type-AOnabotulinum toxin type-A
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01374191

Each answer restates registry values shown on this page.

What is NCT01374191?

NCT01374191 is a phase 2 interventional trial sponsored by Southern Illinois University. It studies 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A in Neuroma.

Who leads NCT01374191?

The registry names Michael A. Neumeister, MD (principal investigator, Southern Illinois University School of Medicine) as the overall official.

Where does NCT01374191 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01374191 study?

The registered drug and biological interventions are 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A.

When did NCT01374191 end?

The registry lists a primary completion date of 31 May 2017 and a study completion date of 30 Sept 2017. The sponsor last updated the record on 26 Aug 2015.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.